An experimental mRNA cancer vaccine developed by Moderna and Merck significantly reduces the risk of melanoma returning or causing death when combined with immunotherapy, according to late-stage clinical trial results presented at the European Society for Medical Oncology Congress in Madrid.
Phase 3 Trial Results for Intismeran Autogene
The Phase 3 trial evaluated 1,137 patients with high-risk melanoma whose tumors had been completely removed surgically. Two-thirds of the participants received doses of the personalized mRNA vaccine, named intismeran autogene, which encodes up to 34 neoantigen fragments identified in each patient’s specific tumor. All trial participants also received pembrolizumab, marketed as Keytruda, a standard checkpoint inhibitor immunotherapy.
Georgina Long, a medical oncologist at Melanoma Institute Australia and the University of Sydney who led the trial, reported that 82.2% of patients who received the vaccine were alive and had not relapsed after two years, compared to 70% in the control group receiving immunotherapy alone. This translates to a 42% reduction in relapses.
How the Personalized Vaccine Technology Operates
The treatment utilizes messenger RNA technology similar to COVID-19 vaccines, but directs immune cells to recognize features unique to an individual’s cancer rather than a virus. Laboratories map 34 different areas in a patient’s tumor DNA and compare them to normal DNA to identify abnormal proteins on the surface of cancer cells. The resulting individualized vaccine instructs the patient’s immune system to target those specific protein markers.
Medical oncologist and Melanoma New Zealand spokesperson Dr. Gareth Rivalland explained that the vaccine pairs with traditional immunotherapies that unmask cancer cells. The idea that the immune system has a role in cancer protection or cancer treatment has been around since the late 1890s,
Rivalland told RNZ.
High Manufacturing Costs Threaten Commercial Adoption
Despite meeting its primary endpoint, the financial and logistical hurdles of customized manufacturing remain uncertain. Miguel Bronchud noted on LinkedIn that while the vaccine slashes recurrence risk, questions remain regarding why the exact mechanism of broad protection is unclear and how widely it will be adopted given high costs.
Financial markets have reacted to the commercial outlook. Moderna shares dropped following the detailed data release due to questions over the vaccine’s impact on distant spread compared to earlier estimates. Meanwhile, analysts and researchers point out that producing individual mRNA treatments requires tumor analysis, target selection, manufacturing, and quality testing within a strict clinical timeframe.
Regulatory Approval Depends on Manufacturing Scalability
Rivalland stated that regulatory approval will depend on manufacturing scalability and cost, noting that agencies like Pharmac will need to assess value for money before broad public funding.
Experts interviewed by New Scientist predict that certain jurisdictions could approve the vaccine as early as 2027. Based on the success of the trial, researchers expect the platform to expand into clinical trials for other cancer types.
Frequently Asked Questions About the Melanoma Vaccine Trial
What specific trial demonstrated the efficacy of intismeran autogene?
The Phase 3 trial evaluated 1,137 patients with high-risk melanoma that had been completely removed surgically, combining the personalized vaccine with pembrolizumab.
How much did the vaccine reduce the risk of melanoma recurrence?
Data presented at the European Society for Medical Oncology Congress showed a 42% reduction in the risk of recurrence or death compared to pembrolizumab alone, with 82.2% of vaccinated patients remaining relapse-free at two years.
When might the personalized cancer vaccine become widely available to patients?
While industry experts predict regulatory approvals in certain jurisdictions by 2027, exact timelines depend on manufacturing scale, commercial pricing, and national health funding decisions such as Pharmac reviews in New Zealand.